DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Morgan Stanley - 1 Mark D Purcell - 1 Sweden's - 1 Sublocade - 1 Thibault Boutherin - 1 Morgan - 1 — CNBC's Michael Bloom - 1
Top related locs:
U.S argenx Novo Indivior
Top related orgs:
Barclays - 1 Bank of America - 1 AstraZeneca - 1 Merck - 1 Lonza - 1 Novo Nordisk - 1 Sandoz Group - 1 AstraZeneca AstraZeneca - 1

Search resuls for: "Sublocade"


2 mentions found


☆ Morgan Stanley likes biopharma as a defensive play — giving one stock 119% upside
  + stars: | 2024-01-22 | by ( Ganesh Rao | ) www.cnbc.com   time to read: +3 min
The biopharmaceutical sector is expected to offer a safe haven from macroeconomic and earnings concerns ahead of final quarterly results from companies, according to Morgan Stanley. Morgan Stanley, however, cautioned that the outlook for drug pricing reform in the U.S. poses risks for the sector. Shares of Indivior , argenx , AstraZeneca , Merck , Lonza, Sweden's Sobi, Novo Nordisk and Sandoz Group were among those listed by Morgan Stanley with a "buy" rating. In a bull case where Sublocade hits $2.2 billion in sales by 2030, Morgan Stanley sees shares rising further to 3,500 British pence. Novo Nordisk Shares of Novo Nordisk , a leader in diabetes and obesity drugs, offer a 9.4% upside, according to Morgan Stanley.
Persons: Morgan Stanley, Mark D Purcell, Sweden's, Sublocade, Thibault Boutherin, Morgan, — CNBC's Michael Bloom Organizations: Barclays, Bank of America, AstraZeneca, Merck, Lonza, Novo Nordisk, Sandoz Group, AstraZeneca AstraZeneca, British pharma, EU Locations: U.S, argenx, Novo, Indivior
☆ Warren tells FTC she is "particularly concerned" about Amgen and Indivior deals
  + stars: | 2023-01-26 | by ( ) www.reuters.com   time to read: +2 min
Warren said that both Amgen and Horizon Therapeutics "have engaged in brazen price increases," including on Amgen's Enbrel for arthritis and Horizon’s Krystexxa, a gout medication. She noted that the FTC had settled with Indivior and its former parent over its attempt to protect its monopoly of the opioid addiction treatment Suboxone. Indivior makes Sublocade -- a slow-release treatment for opioid addiction that is administered monthly. "The FTC should strongly consider Indivior's history of anti-competitive and deceptive practices when evaluating howIndivior might behave after this potential transaction is completed," wrote Warren. Warren noted that the FTC, which has long focused on healthcare mergers, said in 2021 that it would prioritize pharmaceutical acquisitions.
0 next >>
Total: 2